Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Vigabatrin submitted by Zydus Lifesciences Limited. This action constitutes a supplemental appro…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Edenbridge Pharmaceuticals LLC.)
FDA approved a supplemental application for Vigabatrin submitted by Edenbridge Pharmaceuticals LLC, authorizing the marketing of the generic…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Hikma Pharmaceuticals USA Inc)
The FDA approved a supplemental application for Vigabatrin from Hikma Pharmaceuticals USA Inc., updating the drug's labeling.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for Vigabatrin from Par Health USA, LLC under the ANDA (ANDA208218). This action represents added re…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Vigabatrin submitted by Amneal Pharmaceuticals NY LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-18FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for SABRIL (vigabatrin) filed by Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Dr. Reddys Laboratories Inc.,)
FDA approved a supplemental application for Vigabatrin submitted by Dr. Reddys Laboratories Inc.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Carnegie Pharmaceuticals LLC)
The FDA approved a supplemental application for Vigabatrin submitted by Carnegie Pharmaceuticals LLC.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Vigabatrin from Ascend Laboratories, LLC (ANDA 213375).
-
EMA approval · 2026-03-11EMA Authorised: Vimpat (lacosamide) — UCB Pharma SA
The European Medicines Agency granted authorisation for Vimpat (lacosamide) for epilepsy, with UCB Pharma SA as the marketing authorisation …
-
FDA approval · 2026-03-06FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for carbamazepine from Apotex Corp., granting approval for the generic product under ANDA075948. The…
-
FDA approval · 2026-03-06FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals, updating the labeling.
-
FDA approval · 2026-03-06FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals, Inc. This action confirms regulat…
-
FDA approval · 2026-02-25FDA Approved: LAMOTRIGINE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' original ANDA for generic lamotrigine.
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a generic version of brivaracetam. The generic is approved for the treatment of partial…
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original abbreviated new drug application for a generic Brivaracetam product from Novadoz Pharmaceuticals LLC. Brivaracetam…
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Zhejiang Poly Pharm. Co., Ltd.)
FDA approved Zhejiang Poly Pharm. Co., Ltd.'s brivaracetam as a generic version, expanding access to the antiepileptic medication.
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' generic version of brivaracetam through an original ANDA, expanding access to an antiseizure medicat…
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a generic injectable form of brivaracetam under an ANDA for PAI Holdings (PAI Pharma).
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM ORAL SOLUTION — Original Application (Florida Pharmaceutical Products, LLC)
FDA approves Brivaracetam Oral Solution as an original application generic product by Florida Pharmaceutical Products, LLC.
-
FDA approval · 2026-02-19FDA Approved: BRIVARACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original abbreviated new drug application for brivaracetam from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2026-02-17FDA Approved: GABAPENTIN — Supplemental Application (Creekwood Pharmaceuticals LLC)
The FDA approved a supplemental application for gabapentin filed by Creekwood Pharmaceuticals LLC.
-
EMA approval · 2026-02-16EMA Authorised: Pregabalin Zentiva (pregabalin) — Zentiva, k.s.
EMA authorised a generic pregabalin product, Pregabalin Zentiva, for anxiety disorders and epilepsy.
-
FDA approval · 2026-02-12FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for gabapentin by Ascend Laboratories, LLC, updating regulatory approval for this generic product.
-
FDA approval · 2026-02-02FDA Approved: PREGABALIN — Supplemental Application (Tris Pharma Inc)
FDA approves Tris Pharma Inc's supplemental application for pregabalin.